More than 30% of the world's population are anaemic with serious medical consequences. Red blood cell transfusion is the mainstay to correct anaemia, but it is also one of the top five overused procedures, and carries its own risks. Patient blood management (PBM) is a patient-centred and multidisciplinary approach to manage anaemia, minimize iatrogenic blood loss and harness tolerance to anaemia to improve patient outcome. Despite resolution, 63Á12 of the World Health Organization in 2010 endorsing PBM and current guidelines with evidence-based recommendations on the use of diagnostic and therapeutic measures, PBM is still not implemented in many hospitals. Here, we present a short review of recent developments in the field of PBM.
Introduction
Patient Blood Management (PBM) is an interdisciplinary diagnostic, behavioural and therapeutic concept, which reduces and avoids unnecessary blood loss and focuses on the rational handling of blood components. Based on the possibilities to strengthen and to preserve patients' own blood resources and to enable safe handling of donor blood, the World Health Assembly (WHA) has endorsed PBM in 2010 (WHA63Á12) [1] . The use of PBM in clinical practice follows the three main pillars: (1) Comprehensive anaemia management; (2) Minimisation of iatrogenic (unnecessary) blood loss; (3) Harness and optimize the patientspecific physiological tolerance of anaemia [2] [3] [4] .
Patient blood management
Since the term Patient Blood Management was initially mentioned in the literature in 2007, enormous efforts have been made to address anaemia management, to preserve patient's own blood resources and to ensure optimal blood use. About 10 years ago, Gombotz et al. conducted the Austrian benchmark study on blood utilisation in elective surgical patients in 18 hospitals. It was one of the first studies showing the high predictability (>95%) of blood transfusion based on (1) the level of preoperative anaemia, (2) the volume of perioperative blood loss and (3) the transfusion threshold [5] . Implementation strategies should therefore target complementary measures of all three PBM pillars to specifically minimise risk factors associated with anaemia and transfusion. Over the last decade, single interventions or different aspects of PBM have been implemented into clinical practice; however, only the minority of hospitals have yet adopted measures of all the three pillars. So far, more than 100 individual PBM measures addressing the three main pillars have been defined based on the broad interdisciplinary fields (for example anaesthesia, surgery and central laboratory) and temporal application (pre-, intra-to postoperative) [6] . The great advantage of this PBM bundle concept is that the selection can be dynamically adapted to the individual's local financial and personal resources as well as the respective focus of each hospital.
The overall clinical efficacy of PBM has been confirmed by many recent large studies encompassing several hundred thousand of patients [7] [8] [9] [10] [11] [12] [13] [14] . Overall, implementation of PBM is associated with a reduced transfusion rate of allogeneic blood products by about 40%, improved clinical outcomes, a reduced complication rate, reduced length of hospital stay and reduced costs. In detail, Meybohm et al. measures (i.e. preoperative optimization of haemoglobin levels, blood-sparing techniques and standardization of transfusion practice). While the mean number of red blood cell transfused per patient was reduced from 1Á21 AE 0Á05 to 1Á00 AE 0Á05, the primary composite endpoint was 6Á53% in the pre-PBM versus 6Á34% in the PBM cohort [9]. Keding et al. recently demonstrated PBM as a quality improvement tool that is associated with better mid-term surgical oncologic outcome. Based on a retrospective analysis of 836 patients who underwent visceral oncologic surgery (n = 389 before and n = 447 after PBM), patients in the PBM group presented significantly more often normal haemoglobin values before surgery (56Á6 vs. 35Á7%), had significantly less RBC transfusion (3Á0 AE 6Á9 vs. 5Á5 AE 11Á1 units/patient) and showed a significant improved 2-year overall survival (80Á1 vs. 67Á0%) [15] . Leahy et al. previously published a retrospective study of 605 046 patients admitted to four major adult tertiarycare hospitals between July 2008 and June 2014 in Western Australia. Comparing final year with baseline, units of RBCs, FFP and platelets transfused per admission decreased by 41%, representing a saving of AU $18 507 092 and between AU$80 million and AU$100 million estimated activity-based savings. Mean pre-transfusion haemoglobin levels decreased from 7Á9 to 7Á3 g/dl, and anaemic elective surgery admissions decreased from 20Á8% to 14Á4%. Single-unit RBC transfusions increased from 33Á3% to 63Á7%. Implementation of this unique, jurisdiction-wide PBM programme was associated with risk-adjusted reductions in hospital mortality (odds ratio [OR]: 0Á72; 95% confidence interval [CI]: 0Á67-0Á77), length of stay (incidence rate ratio: 0Á85; 95% CI: 0Á84-0Á87), hospital-acquired infections (OR: 0Á79; 95% CI: 0Á73-0Á86) and acute myocardial infarction-stroke (OR: 0Á69; 95% CI: 0Á58-0Á82) [7] .
Notably, different characteristics of published studies may contribute to clinical heterogeneity and recent lack of clinical PBM implementation. Additional large prospective randomized controlled trials with high methodological quality might be warranted. Based on current evidence and international guidelines supporting the beneficial effects of PBM, however, any theoretical prospective trial randomizing patients either to an 'up-todate' multimodal PBM programme or a 'historic' control group not receiving any attention to prevent anaemia and to minimise blood loss, not receiving any treatment of iron deficiency (anaemia) or coagulation management in bleeding patients, is probably unethical.
Anaemia management before an intervention
In 18 large observational studies encompassing more than 650 000 surgical patients, the prevalence of preoperative anaemia varied between 10Á5% and 47Á9% [16] . Preoperative screening should include evaluation and management of anaemia. From a practical point of view, patients scheduled for surgical procedures with expected blood loss (>500 ml) or a ≥10% probability of red blood cell (RBC) transfusion should be identified and assessed at the earliest opportunity, and be screened for iron-deficiency and other likely causes of anaemia [17] [18] [19] [20] [21] [22] . The availability of an easy-to-follow, diagnostic algorithm is desirable [19] . Intravenous iron is efficacious, safe [23] and should be used in patients in whom oral iron is not tolerated, or if surgery is planned in less than 4-6 weeks after the diagnosis of iron deficiency [24] [25] [26] [27] . It is notable that most effective increments of Hb-levels (ΔHb of 1Á5 and 3Á9 g/dl) can be reached when intravenous iron was administered between 2 and 4 weeks before surgery [25, 28] . Nevertheless, treatment a few days before surgery has also been shown to effectively increase Hb-level postoperatively and to reduce transfusion rate [29] . Elective surgery should be postponed until preoperative anaemia has been appropriately classified and treated, if possible.
Minimisation of iatrogenic (unnecessary) blood loss
A series of surgical procedures carry high risks for bleeding and transfusion that can be sufficiently addressed by PBM measures. For example, orthopaedic surgical procedures such as total knee arthroplasty or total hip arthroplasty are associated with extensive blood loss up to 1500 ml [30] . The average cardiac surgery patient loses between 500 and 1200 ml of blood perioperatively, and about 5% of all cardiac surgery patients are re-explored due to excessive bleeding [31] . In this respect, intraoperative RBC recovery and autologous transfusion is highly effective to minimize allogeneic RBC transfusion. A recent meta-analysis showed that the use of cell salvage reduced the number of patients exposed to allogeneic RBCs by 39% [32] .
Blood loss associated with invasive laboratory testing can either cause or aggravate hospital-acquired anaemia which is associated with increased length of stay and complications [33] . Reduction of blood drawn for laboratory analyses can be achieved by avoiding unnecessary laboratory tests and lower frequency of sampling [34] and using the smallest collection tube size that is practical for the required analysis. Further reduction of phlebotomy associated blood loss can be achieved by using closed in-line flush blood sampling devices for arterial (and central) lines [35] . Advanced perioperative coagulation monitoring and management are crucial for avoiding unnecessary blood loss and should be a precondition before RBC transfusion is considered. In this respect, the use of a coagulation algorithm is recommended [36, 37] encompassing preoperative assessment [38] , ensuring basic conditions for haemostasis (e.g. temperature, calcium, pH), reversal of anticoagulants, point-of-care diagnostics in bleeding (e.g. coagulopathic) patients (if available), and optimized coagulation management with the use of clotting factor concentrates [39] [40] [41] [42] . To reduce surgical blood loss, tranexamic acid should be used unless contraindicated (i.e. history of venous thromboembolic events) [43, 44] .
Harness and optimize the patient-specific physiological tolerance of anaemia Several trials have been conducted to compare outcome in patients undergoing either a restrictive or a liberal transfusion strategy. Interestingly, outcome measures (i.e. mortality, length of hospital stay, acute kidney failure) were similar in critical care patients [45] , patients undergoing cardiac surgery [46] , patients with hip fracture [47] or acute upper gastro-intestinal haemorrhage [48] either assigned to a pre-transfusion haemoglobin trigger of below 7-8 g/dl or 9-10 g/dl respectively. In order to optimize utilization of allogeneic blood products, it may be beneficial to adopt a physician order entry with a clinical decision support based on electronic medical records [12, 49] . Thereby, indication for transfusion considering patient specific factors (e.g. age, diagnosis, comorbidities, surgical or non-surgical setting), signs/symptoms of acute anaemia, laboratory values (e.g. haemoglobin) and presence or absence of bleeding) can be confirmed with required checkboxes [50] . If a RBC transfusion is indicated in case of patients not actively/acutely bleeding, only a single RBC should be administered. We suggest that the indication for transfusion must also take into consideration patient-specific factors (e.g. age, diagnosis, comorbidity), laboratory values (e.g. haemoglobin concentration, platelet count, coagulation tests), the existence of a coagulopathy and defined physiological factors (oxygen supply and haemodynamic status). At this point, it remains unclear whether cardiovascular risk patients, geriatric or oncological patients will benefit more from a higher transfusion trigger than from the one currently recommended. A clinical corridor for making medical discretionary decisions is still needed in this context.
Conclusion
The body of evidence about the benefits of PBM is large. Interestingly, a multidisciplinary, multimodal PBM programme might have the highest potential in reducing RBC utilization and improving postoperative outcome. Patient blood management in elective total hip-and knee-replacement surgery (part 2): a randomized controlled trial on blood salvage as transfusion alternative using a restrictive transfusion policy in patients with a preoperative hemoglobin above 13 g/dl.
